Berglund L
Department of Medicine, College of Physicians and Surgeons of Columbia University, New York, New York, USA.
Curr Opin Lipidol. 1995 Feb;6(1):48-56. doi: 10.1097/00041433-199502000-00011.
Lipoprotein (a) has been implicated with an increased risk of atherosclerosis and cardiovascular disease. Recently, considerable progress has been made toward understanding the importance of genetics in the regulation of plasma levels of lipoprotein (a). However, the issue as to whether lipoprotein (a) levels should be treated is still debated and furthermore the possibilities to influence lipoprotein (a) levels remain limited. The potential clinical importance of lipoprotein (a) has stimulated interest in the dietary and pharmacologic agents that affect this lipoprotein. At present, only a few of the existing therapeutic tools, such as nicotinic acid and estrogens, have been found to consistently affect lipoprotein (a).
脂蛋白(a)与动脉粥样硬化和心血管疾病风险增加有关。最近，在理解遗传学在调节血浆脂蛋白(a)水平中的重要性方面取得了相当大的进展。然而，脂蛋白(a)水平是否应接受治疗的问题仍存在争议，而且影响脂蛋白(a)水平的可能性仍然有限。脂蛋白(a)潜在的临床重要性激发了人们对影响这种脂蛋白的饮食和药物制剂的兴趣。目前，仅发现少数现有的治疗手段，如烟酸和雌激素，能持续影响脂蛋白(a)。
